# Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir

> **NCT05423834** · — · ACTIVE_NOT_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 1800 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Tenofovir alafenamide
- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT05423834
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-01
- **Primary completion:** 2025-12-21
- **Final completion:** 2026-12-31
- **Target enrollment:** 1800 (ESTIMATED)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05423834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05423834, "Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05423834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*